CLINICAL TRIAL: PHASE I TRIAL OF BORTEZOMIB AND FLAVOPIRIDOL WITH RECURRENT B-CE

临床试验：硼替佐米和弗拉吡多与复发性 B-CE 的 I 期试验

• 批准号: 7950855
• 负责人: Steven Grant
• 金额: $ 12.04万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950855
• 关键词: Bortezomib; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; Institution; Investigational Drugs; Laboratory Study; Lymphoma; Malignant Neoplasms; Multiple Myeloma; New Agents; Patients; Pharmaceutical Preparations; Phase I Clinical Trials; Recruitment Activity; Recurrence; Research; Research Personnel; Resources; Source; United States National Institutes of Health; combat; flavopiridol; improved

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Although there are many treatments for lymphomas, myelomas, and related cancers, most patients are not cured. The general purpose of this study is to improve the treatment of lymphomas, myeloma, and related cancers. Bortezomib is a new agent approved for the treatment of myeloma. Laboratory studies suggest that Bortezomib might be helpful in combating myelomas in combination with Flavopiridol (an investigational drug). This study will help identify the appropriate doses for the combination of the two drugs. This study will recruit approx 20 subjects.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 尽管对淋巴瘤，骨髓瘤和相关癌症有很多治疗方法，但大多数患者尚未治愈。 这项研究的一般目的是改善淋巴瘤，骨髓瘤和相关癌症的治疗。 硼替佐米是一种新的药物，获得了用于治疗骨髓瘤的新药物。 实验室研究表明，硼替佐米可能有助于与黄髓瘤与黄叶肽（一种研究药物）结合使用。 这项研究将有助于确定两种药物组合的适当剂量。 这项研究将招募大约20名受试者。